共 50 条
Liver stiffness measurement trajectory analysis for prognosis in patients with chronic hepatitis B and compensated advanced chronic liver disease
被引:0
作者:
Jiang, Hao
[1
,2
]
Yu, Hongsheng
[1
,2
]
Hu, Can
[1
,2
]
Huang, Yinan
[1
,2
]
Yang, Bilan
[3
]
Xi, Xiaoli
[1
,2
]
Lei, Yiming
[1
,2
]
Wu, Bin
[1
,2
]
Yang, Yidong
[1
,2
]
机构:
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Gastroenterol, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[2] Guangdong Prov Key Lab Liver Dis Res, Guangzhou, Guangdong, Peoples R China
[3] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou 510230, Peoples R China
基金:
国家重点研发计划;
中国国家自然科学基金;
关键词:
Chronic hepatitis b;
Compensated advanced chronic liver disease;
Fibroscan;
Liver-related events;
Prognosis;
Trajectory;
PROGRESSION;
ELASTOGRAPHY;
FIBROSIS;
BIOPSY;
RISK;
D O I:
10.1016/j.aohep.2025.101788
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Introduction and Objectives: Liver stiffness measurements (LSMs) offer a noninvasive method for monitoring liver disease development. This study evaluated the prognostic value of different LSM trajectories in chronic hepatitis B (CHB) and compensated advanced chronic liver disease (cACLD) patients. Materials and Methods: We retrospectively analyzed 1272 CHB and cACLD patients with at least two LSMs, applied group-based trajectory modeling (GBTM) to identify distinct LSM trajectories, and used a Cox model to analyze their associations with liver-related events (LREs) and mortality risk. Results: Patients were categorized into five groups with distinct LSM trajectories: 67 (8.5 %), 13 (11 %), 36 (23.5 %), 34(27.6 %) and 23 (25.0 %) developed LREs in Groups 1-5. The low stable trajectory (Group 3), the medium gradual decrease trajectory (Group 4) and high quickly decrease followed by increase trajectory (Group 5) had higher LREs risks than the low gradual decrease trajectory (Group 1) (adjusted HRs 2.26, 2.39, 2.67; 95 % CIs 1.50-3.40, 1.57-3.66, 1.61-4.43, respectively). Similar elevated risks were observed for hepatic decompensation, hepatocellular carcinoma (HCC), liver-related and all-cause mortality, except that there was no significant difference in the risk of HCC between Groups 4 and 1 (aHR 0.66, 0.36-1.23). When comparing Group 1 with the medium quickly decrease trajectory (Group 2), no significant differences were noted in the prognosis (P > 0.05). Notably, age over 40, high LSM, low PLT, and high total bilirubin were linked to high-risk trajectories (Groups 3-5). Conclusions: Monitoring LSM trajectories improves prognostic prediction in CHB and cACLD compared with single measurements and may guide personalized treatment strategies. (c) 2025 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页数:9
相关论文